↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(von der Lehr N) "

Search: WFRF:(von der Lehr N)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Akhoondi, S, et al. (author) The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007) 2008 In: CANCER RESEARCH. - 0008-5472. ; 68:4, s. 1245-1245 Journal article (other academic/artistic)
2.	Malyukova, A, et al. (author) The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling 2007 In: Cancer research. - 0008-5472. ; 67:12, s. 5611-5616 Journal article (peer-reviewed)
3.	Tötterman, Thomas H., et al. (author) Targeted superantigens for immunotherapy of haematopoietic tumours 1998 In: Vox Sanguinis. - 0042-9007 .- 1423-0410. ; 74:Supp 2, s. 483-487 Journal article (peer-reviewed)abstract With the exception of childhood common acute lymphoblastic leukaemia (cALL), treatment of other hematopoietic B cell lineage tumours such as non-Hodgkin's lymphoma (B-NHL), adult ALL and multiple myeloma (MM) is unsatisfactory. Similarly, the therapeutic outcome of acute and chronic myeloid leukaemia (AML, CML) is frequently dismal. At the same time, leukaemia/lymphoma cells represent ideal targets for immunotherapy. The present review summarizes our preclinical experience with a novel type of cytotoxic T cell based immunotherapy for B-lineage and myeloid tumours. Staphylococcal enterotoxin-derived superantigens (SAgs) are among the most potent T cell activators known, linking the T cell receptor to HLA-DR on natural target cells. SAgs were genetically engineered to reduce DR binding and were then fused to Fab parts of tumour-directed monoclonal antibodies (mAbs). Using these "targeted" SAgs, highly efficient lysis of B-lineage (B-NHL, B-CLL, ALL, MM) and myeloid (AML, CML) tumour cells by T-cells was achieved in vitro and in an animal model. We are entering an interesting era of innovative cancer therapy based on novel man-made biotherapeutic agents.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (3)

Type of content: peer-reviewed (2); other academic/artistic (1)

Author/Editor: von der Lehr, N (3); Corcoran, M. (2); Grander, D (2); Spruck, C (2); Sangfelt, O (2); Widschwendter, M (1); show more...; Hansson, J. (1); Lendahl, U (1); Dohlsten, M (1); Klotz, K (1); Akhoondi, S (1); Sun, D (1); Apostolidou, S (1); Maljukova, A (1); Capeda, D (1); Fiegl, H (1); Dafou, DMC (1); Marth, C (1); Mueller-Holzner, E (1); Dagnell, M (1); Nejad, SZ (1); Nayer, BN (1); Zali, MR (1); Egyhazi, S (1); Petersson, F (1); Sangfelt, P (1); Nordgren, H (1); Reed, SI (1); Heyman, M. (1); Lindeberg, M. (1); Kristensson, K (1); Tötterman, Thomas H. (1); Kalland, T (1); Malyukova, A (1); Dohda, T (1); Einarsson, A (1); Akhondi, S (1); Gidlöf, C. (1); Ragnarsson, L. (1); Högbom, E. (1); Soegaard, M. (1); show less...

University: Karolinska Institutet (2); Uppsala University (1)

Language: English (3)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view